Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Bob Swift who wrote (2538)	4/26/1999 9:29:00 AM
From: BMcV	Respond to of 10280

Forest has an interesting history. When the current management took over the company, they sold mostly confectionary products. They saw an opportunity in buying secondary pharmaceutical lines from major manufacturers, developing and marketing them. They were from the start, therefore, less an R&D than a sales outfit. A little like SEPR, whose management has said they believe the marketing department should lead R&D, not the other way around. Did this new drug come out of their labs? If so, they have traced the path from pharmaceutical marketer to drug developer and discover that SEPR has outlined as their strategy.